Skip to main content

Brexafemme Side Effects

Generic name: ibrexafungerp

Medically reviewed by Last updated on Sep 9, 2023.

Note: This document contains side effect information about ibrexafungerp. Some dosage forms listed on this page may not apply to the brand name Brexafemme.

Applies to ibrexafungerp: oral tablet.


Oral route (Tablet)

Warning: Risk of Embryo-Fetal ToxicityIbrexafungerp is contraindicated in pregnancy because it may cause fetal harm based on findings from animal reproductive studies.For females of reproductive potential, verify that the patient is not pregnant prior to initiating ibrexafungerp treatment. Reassessing pregnancy status prior to each dose is recommended when ibrexafungerp is used monthly for 6 months for reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC).Advise females of reproductive potential to use effective contraception during treatment of vulvovaginal candidiasis (VVC) and throughout the 6-month treatment period for reduction in the incidence of RVVC with ibrexafungerp and, for 4 days after the last dose.

Serious side effects of Brexafemme

Along with its needed effects, ibrexafungerp (the active ingredient contained in Brexafemme) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking ibrexafungerp:

Less common

Other side effects of Brexafemme

Some side effects of ibrexafungerp may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to ibrexafungerp: oral tablet.


Frequency not reported: Rash


Very common (10% or more): Diarrhea (up to 16.7%), nausea (up to 11.9%), abdominal pain (up to 11.4%)

Common (1% to 10%): Vomiting

Frequency not reported: Flatulence

Abdominal pain included abdominal pain, upper abdominal pain, lower abdominal pain, and abdominal discomfort.


Common (1% to 10%): Urinary tract infection

Frequency not reported: Dysmenorrhea, vaginal bleeding


Frequency not reported: Elevated transaminases


Frequency not reported: Hypersensitivity reaction


Frequency not reported: Back pain

Nervous system

Very common (10% or more): Headache (up to 17.6%)

Common (1% to 10%): Dizziness

Dizziness included dizziness and postural dizziness.


Common (1% to 10%): Fatigue

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.